22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- China rushes farm machinery to key grain belt as rain threatens harvest
- Xinjiang scenic area suspends hiking after heavy snowstorm
- Typhoon Matmo weakens after hitting South China's Guangxi, relief efforts underway
- Rise of 'granfluencers' boosts confidence, silver economy
- Vibrant China during holiday: Museums beyond artifacts
- New type of matsutake hunters and traders
